Organon & Co. OGN 深 沪
等待开盘 02-03 09:30:00 美东时间
8.20
-0.340
-3.98%
华盛通- 最 高8.53
- 今 开8.53
- 成交量 559.10万股
- 最 低 8.07
- 昨 收 8.54
- 总市值 21.32亿
- 52周最高 16.89
- 市盈率 静 2.46
- 换手率 2.15%
- 52周最低 6.16
- 委 比 -96.08%
- 总股本 2.60亿
- 历史最高 36.055
- 量 比 1.12
- 振 幅 5.39%
- 历史最低 6.16
- 每 手 1
- 风险率 2.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What Does the Market Think About Organon & Co?
Organon & Co's (NYSE:OGN) short interest as a percent of float has risen 5....
01-30 03:00
Organon & Co. to Report Financial Results and Host Conference Call
Organon & Co. to Report Financial Results and Host Conference Call Organon & Co. will release its fourth quarter and full year 2025 financial results on February 12, 2026. Results will be available prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET. Interested parties may
01-29 20:30
BUZZ-India's Sun Pharma-Organon $10 bln deal strategic despite high leverage, say analysts
BUZZ-India's Sun Pharma-Organon $10 bln deal strategic despite high leverage, say analysts ** India's Sun Pharmaceutical SUN.NS has submitted a non-binding offer to acquire US-headquartered Organon OGN.N for $10 billion, Economic Times reported on Monday ** Shares of SUN down 3% since Monday ** Jeff
01-21 15:06
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
Sun Pharma is evaluating a potential $10 billion acquisition of Organon, a move that could become India's largest cross-border pharma deal.
01-20 23:31
Organon gains on report of Sun Pharmaceutical interest
Organon (OGN) rose 6.5% after a report that India's Sun Pharmaceutical made a non-binding offer to acquire the company. Sun Pharmaceutical has tied up acquisition financing for a deal in the form of ...
01-20 22:38
Organon poised to extend rally to seventh consecutive session
Organon & Co (OGN) was on track to extend its gains for the seventh straight session on Thursday after its shares rose 2.08% to $8.36 at around noon. Between December 30 and January 7, the company’s s...
01-09 01:22
Organon Signs Commercialization Agreement For Daiichi Sankyo's Nilemdo To Strengthen Cardiovascular Disease Portfolio In France And Nordic Countries
The agreement builds on Organon's cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration
01-08 14:34
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Barclays Initiates Coverage On Organon with Underweight Rating, Announces Price Target of $7.5
Barclays analyst Glen Santangelo initiates coverage on Organon (NYSE:OGN) with a Underweight rating and announces Price Target of $7.5.
2025-12-09 23:09
复星医药子公司复宏汉霖与Organon共同宣布美国首个帕妥珠单抗生物类似药POHERDY获美国FDA批准
（来源：复星医药） 转自：复星医药 中国上海 & 美国新泽西州泽西市，2025年11月17日 —— 复星医药子公司复宏汉霖（2696.HK）与O...
2025-11-17 18:51
